NEW YORK, Nov. 21, 2016 /PRNewswire/ -- Attorney
Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies
investors that a class action lawsuit has been filed against
Dynavax Technologies Corporation ("Dynavax" or the "Company")
(DVAX) and certain of its officers, and is on behalf of
shareholders who purchased or otherwise acquired Dynavax
securities March 10, 2014 and
November 11, 2016 both dates
inclusive (the "Class Period"). Such investors are advised to
join this case by visiting the firm's site:
www.bgandg.com/dvax.
This class action seeks to recover damages against Defendants
for alleged violations of the federal securities laws under the
Securities Exchange Act of 1934 (the "Exchange Act").
The Complaint alleges that throughout the Class Period,
Defendants made materially false and misleading statements and/or
failed to disclose: (1) that the phase 3 HBV-23 trial for Dynavax's
lead vaccine product HEPLISAV-B was not designed in accordance with
the U.S. Food and Drug Administration's concerns and issues; (2)
that Dynavax failed to provide sufficient information to the FDA in
its Revised Biologics License Application for the drug; (3) that
Dynavax's resources will not be sufficient for the Company to
advance the HEPLISAV-B program on its own; and (4) consequently,
Dynavax's financial statements and statements about its business,
operations, and prospects were false and misleading and/or lacked a
reasonable basis.
On November 14, 2016, Dynavax
dropped over 62% on intraday trading after Dynavax announced that
it had received a Complete Response Letter from the U.S. Food and
Drug Administration, requesting additional information "including
clarification regarding specific adverse events of special interest
(AESIs), a numerical imbalance in a small number of cardiac events
in a single study (HBV-23), new analyses of the integrated safety
data base across different time periods, and post-marketing
commitments."
A class action lawsuit has already been filed. If you wish to
review a copy of the Complaint you can visit the firm's site:
www.bgandg.com/dvax or you may contact Peretz Bronstein, Esq. or his Investor Relations
Analyst, Yael Hurwitz of Bronstein,
Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss
in Dynavax you have until January
17, 2017 to request that the Court appoint you as lead
plaintiff. Your ability to share in any recovery doesn't
require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation
boutique. Our primary expertise is the aggressive pursuit of
litigation claims on behalf of our clients. In addition to
representing institutions and other investor plaintiffs in class
action security litigation, the firm's expertise includes general
corporate and commercial litigation, as well as securities
arbitration. Attorney advertising. Prior results do not
guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com
Logo - http://photos.prnewswire.com/prnh/20161114/439152LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-notifies-investors-of-class-action-against-dynavax-technologies-corporation-dvax--lead-plaintiff-deadline-january-17-2017-300366814.html
SOURCE Bronstein, Gewirtz & Grossman, LLC